SP187 is widely utilized in the pharmaceutical industry as a potent inhibitor of heat shock protein 90 (HSP90). This protein plays a critical role in the stabilization and function of numerous client proteins involved in cancer progression. By inhibiting HSP90, SP187 disrupts the stability of these client proteins, leading to their degradation and ultimately inhibiting cancer cell growth and survival. This makes it a promising candidate for the development of anticancer therapies, particularly in targeting tumors that are resistant to conventional treatments. Additionally, SP187 is being explored for its potential in treating neurodegenerative diseases, as HSP90 inhibition can help reduce the accumulation of misfolded proteins, a hallmark of conditions like Alzheimer's and Parkinson's disease. Its application in research also extends to studying the role of HSP90 in cellular stress responses and protein homeostasis.